로딩 중…
지수 로딩 중…
현대ADM
187660· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩5,950-4.03%
2026-06-19
Price Chart
현대ADM+374.10%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 330.02B KRW |
| Revenue | 8.75B KRW |
| Net Income | -869.4M KRW |
| Total Assets | 42.49B KRW |
| Net Assets | 31.89B KRW |
| Employees | 159 |
| Value | |
| P/B | 10.35x |
| P/S | 37.71x |
| EV/EBITDA | 275.43x |
| FCF Yield | -1.58% |
| Profitability | |
| ROE | -2.73% |
| ROA | -2.05% |
| Op. Margin | 13.80% |
| Revenue Growth | -23.52% |
| Financial Health | |
| Debt Ratio | 133.22% |
| Total Debt | 5.00B KRW |
| FCF | -5.22B KRW |
| Cash | 2.24B KRW |
| Current Ratio | 0.60x |
| Net Debt/EBITDA | 2.29x |
| Performance | |
| 1Y Return | 374.10% |
| 1M Return | -23.82% |
| From 52W High | -72.33% |
| 1Y MDD | -68.13% |
| Trading | |
| Volume | 603,826 shares |
| Foreign Own. | 4.92% |
| Per Share | |
| EPS | -260 KRW |
| BPS | 582 KRW |
Company Info
Established in 2003, this Contract Research Organization (CRO) was acquired by Hyundai Bioscience in 2024. It holds exclusive rights to drug delivery technology and provides comprehensive services to pharmaceutical companies and bio-ventures, including clinical trial design, monitoring, and data management. The company is developing breast and lung cancer treatments using inorganic material-based drug delivery system technology. It aims to become a global specialized oncology company through digital clinical trials leveraging AI, Big Data, and remote monitoring. Hyundai ADM is headquartered in Jongno-gu, Seoul.